Denali Therapeutics (NASDAQ:DNLI) Trading 9.8% Higher – What’s Next?

Denali Therapeutics Inc. (NASDAQ:DNLI) rose 9.8% on Wednesday . The stock traded as high as $20.58 and last traded at $20.58. Approximately 93,724 shares were traded during trading, a decline of 91% from the average daily volume of 1,002,677 shares. The stock had previously closed at $18.74.

Analyst Ratings Changes

A number of analysts have commented on DNLI shares. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research report on Wednesday. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, HC Wainwright cut their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Stock Up 0.8 %

The company has a 50 day simple moving average of $23.32 and a two-hundred day simple moving average of $24.74.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the company posted ($0.72) earnings per share. On average, equities analysts anticipate that Denali Therapeutics Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 15,558 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now directly owns 178,066 shares of the company’s stock, valued at $5,325,954.06. This represents a 8.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the sale, the director now directly owns 111,056 shares in the company, valued at $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,518 shares of company stock valued at $1,469,382 in the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. American Century Companies Inc. raised its holdings in Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after buying an additional 63,058 shares during the period. Dimensional Fund Advisors LP raised its holdings in Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after buying an additional 84,522 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in Denali Therapeutics during the 2nd quarter valued at $249,000. Hsbc Holdings PLC raised its holdings in Denali Therapeutics by 83.1% during the 2nd quarter. Hsbc Holdings PLC now owns 29,642 shares of the company’s stock valued at $668,000 after buying an additional 13,454 shares during the period. Finally, Sei Investments Co. raised its holdings in Denali Therapeutics by 87.8% during the 2nd quarter. Sei Investments Co. now owns 22,670 shares of the company’s stock valued at $526,000 after buying an additional 10,598 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.